What is the success rate of stem cell therapy for ALS (Motor Neurone Disease)?
A reliable success rate for ALS cell therapy is not established. Current evidence does not support predicting benefit by age, disease duration or bulbar status, and an uncontrolled plateau cannot prove treatment effect. Functional decline and survival are distinct endpoints and should not be merged into one percentage. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
What the evidence shows for ALS (Motor Neurone Disease)
Human ALS cell-therapy studies are generally early-phase and heterogeneous, with different products, routes, populations and endpoints. Safety observations and exploratory biomarker changes do not establish slower functional decline or longer survival. No completed pivotal trial has established a stem-cell product as effective standard ALS treatment. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Am I a candidate? → · ALS (Motor Neurone Disease): full overview → · ALS (Motor Neurone Disease) cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- ALS (Motor Neurone Disease): cell-therapy evidence and registered trials
- How much does stem cell therapy for ALS (Motor Neurone Disease) cost? (2026)
- ALS (Motor Neurone Disease) stem cell therapy — your questions answered (2026)
- ALS (Motor Neurone Disease): cell-therapy evidence by therapy class
- MSC vs HSCT for ALS (Motor Neurone Disease): what the registries show